Cited 0 times in
Long-term treatment response after intravitreal bevacizumab injections for patients with central serous chorioretinopathy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 고형준 | - |
dc.date.accessioned | 2021-05-21T16:47:18Z | - |
dc.date.available | 2021-05-21T16:47:18Z | - |
dc.date.issued | 2020-09 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/182561 | - |
dc.description.abstract | Purpose: To investigate long-term treatment response after intravitreal bevacizumab injections (IVBIs) for central serous chorioretinopathy (CSC). Methods: This retrospective, interventional study investigated the medical records of 45 eyes of 44 patients with CSC who underwent IBVIs and completed at least 2-year follow-up period. Complete resolution (CR) was defined as complete resolution of subretinal fluid at least 3 months after the last IVBI. Thick-choroid CSC was defined as mean subfoveal choroidal thickness more than 300.0 μm. The main outcome measure was long-term treatment outcome after IVBIs in patients with CSC. Results: Thirty-five patients (79.5%) were male, and their mean age was 45.5 ± 9.6 years. The mean follow-up period was 35.1 ± 11.5 months. Twenty-two eyes (48.9%) had acute CSC, and 40 eyes (88.9%) achieved CR. Twenty eyes (50.0%) developed recurrence, the mean number of IVBIs to achieve the first CR was not significantly different between eyes with and without recurrences (2.6 ± 1.6 vs. 2.9 ± 1.9; P = 0.658). Thick-choroid CSC was significantly difference between the eyes with and without recurrence (17 eyes, 85.0% vs. eyes, 50.0%; P = 0.020). Among the baseline characteristics, serous pigment epithelial detachment (B = - 2.580, P = 0.032) and thick-choroid (B = 1.980, P = 0.019) were significantly associated with recurrence. Conclusion: Eyes with CSC treated with IVBI and achieving complete resolution of subretinal fluid have 50% chance of recurrence in the long term. Thinner choroid and serous pigment epithelial detachment appear protective for recurrences. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Public Library of Science | - |
dc.relation.isPartOf | PLOS ONE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Bevacizumab / administration & dosage | - |
dc.subject.MESH | Bevacizumab / pharmacology* | - |
dc.subject.MESH | Bevacizumab / therapeutic use | - |
dc.subject.MESH | Central Serous Chorioretinopathy / drug therapy* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Intravitreal Injections | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Recurrence | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Long-term treatment response after intravitreal bevacizumab injections for patients with central serous chorioretinopathy | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Ophthalmology (안과학교실) | - |
dc.contributor.googleauthor | Hae Min Kang | - |
dc.contributor.googleauthor | Jeong Hoon Choi | - |
dc.contributor.googleauthor | Hyoung Jun Koh | - |
dc.contributor.googleauthor | Sung Chul Lee | - |
dc.identifier.doi | 10.1371/journal.pone.0238725 | - |
dc.contributor.localId | A00152 | - |
dc.contributor.localId | A02873 | - |
dc.relation.journalcode | J02540 | - |
dc.identifier.eissn | 1932-6203 | - |
dc.identifier.pmid | 32898167 | - |
dc.contributor.alternativeName | Koh, Hyoung Jun | - |
dc.contributor.affiliatedAuthor | 고형준 | - |
dc.citation.volume | 15 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | e0238725 | - |
dc.identifier.bibliographicCitation | PLOS ONE, Vol.15(9) : e0238725, 2020-09 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.